Posts by Muana Minkoué
NewBiologix announced a licensing agreement with Florabio AS
NewBiologix SA announced a licensing agreement with Florabio AS to genetically engineer their proprietary HEK293 cell line. NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies. Under the terms of the agreement, NewBiologix acquired rights to use…
Read MoreAktiia secures CHF 27 Million
The Neuchâtel-based startup secures CHF 27 Million (USD 30M) in funding from Khosla Ventures and Others. Aktiia mission to revolutionise blood pressure monitoring has gained momentum with the successful closing of our CHF 27 million (USD 30 million) funding round, which was led by Redalpine and included participation from an international investor syndicate…
Read MoreFuture of Health Grant unveils its March 2024 cohort
Startups Resilient SA and Maven Health are among the eight new startups selected by the Future of Health Grant (FoHG) programme. Launched in 2022 by CSS and EPFL Innovation Park to support innovation in digital health, the programme received over 130 applications in its latest call for applications. The eight selected startups will receive…
Read MoreArgá Medtech SA closes oversubscribed Series B
Argá Medtech announces €54 Million oversubscribed series B capital raise. The round was led by the existing investors, Advent Life Sciences (UK) and Earlybird Health (Germany), as well as new investor Gilde Healthcare (the Netherlands) and an undisclosed strategic investor. The financing enables Argá Medtech to advance the development of its innovative CSE™…
Read MoreTwo life sciences startups shortlisted for the 31st Prix Strategis
Testmate Health and Seprify are among the eight semi-finalists of this year’s Prix Strategis. Every year for almost 30 years, HEC Espace Entreprise has awarded the Prix Strategis to some of the most promising Swiss start-up with a prize of CHF 50’000. The Strategis Prize is a springboard for young companies with high…
Read MoreAbionic appoints Patrick Pestalozzi as new CEO to propel company into next growth phase
Abionic SA, a Swiss leader in nanofluidic point-of-care diagnostic solutions, announced the appointment of Patrick Pestalozzi as its new CEO, effective 1 April 2024. A former Management Consultant, Silicon Valley executive, and entrepreneur, Patrick brings to Abionic three decades of global experience. In particular, he previously acted as the Vice-President of Global Strategic…
Read MoreCSEM and ClexBio create a bioreactor to manufacture tissue-engineered cardiovascular implants
A new type of bioreactor that can grow human veins in the lab has been developed by CSEM and ClexBio, a Nordics-based startup specialised in regenerative medicine. Funded by the Research Council of Norway, their solution aims to improve the lives of millions of people suffering from severe chronic venous insufficiency (CVI) by…
Read MoreThe Biopôle Review – 2023 edition
Check out all the key figures from Biopôle’s community, inspiring interviews and more in their latest review. Biopôle, the life sciences campus based in Lausanne, brings together a strong community of industry and academia. It offers a world-class combination of infrastructure, added value services, living space and community engagement where partners can thrive…
Read MoreAtinary and Takeda collaborate to drive innovation in healthcare
Atinary Technologies, a Vaud based startup, announced a strategic collaboration with Takeda, Japanese largest pharmaceutical company. This partnership brings together the two company’s complementary expertise, paving the way for innovative AI solutions poised to transform pharmaceutical R&D and accelerate drug discovery. Through this collaboration, Takeda will leverage Atinary’s leading AI Self-Driving Labs technology,…
Read MoreInnovative materials to combat bacteria
A UNIGE team is developing new alloys with bactericidal properties to combat antibiotic-resistant germs. While crucial to biotechnology, bacteria can also cause severe disease, exacerbated by their increasing resistance to antibiotics. This duality between economic benefits and infectious risks underlines the importance of finding ways to control their development. A team at the…
Read More